USX:STSA - Satsuma Pharmaceuticals Inc Satsuma Pharmaceuticals Inc
Sector: Financials, Industry: Regional Banks
Next Earnings: 9 May 2024
Add to Watchlist
   
Add Alert 


Yahoo Finance Note: This stock seems to be inactive

USD 1.1    -0.01 (-0.90%)

7 Jun 2023


Loading...
Loading...
Loading...

General

CEO: Mr. John A. Kollins MBA

IPO: 2019-09-13

Headquarters: US

Employees: 25

Homepage

Description

Satsuma Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing a novel therapeutic product for the treatment of migraine. Its product candidate, STS101, is a drug-device combination of a dry-powder formulation of dihydroergotamine mesylate, or DHE, which can be self-administered with a pre-filled, single-use, nasal delivery device.

Your Holdings
Dashboard
Portfolio
Options

Tools
Screener
Watchlist
Alerts
Notes
Community
Forum
Blog
YouTube
Shared Portfolios
Shared Screeners

Collab with Brokerages
Moomoo x StocksCafe
Tiger x StocksCafe

Help
Quickstart Guides
StocksCafe Academy
StocksCafe Youtube Channel

About StocksCafe
Our Story
Send Feedback
Pricing
Market
Singapore
Hong Kong
Tokyo
Kuala Lumpur
United States
London
Shenzhen
Shanghai
Bombay
National (India)
Indexes
Singapore Savings Bonds
Singapore T-Bills
CoinGecko
Your Account
Settings
Subscriptions
Referrals
Messages
Profile
YouTube
Server T4

About · FAQs · StocksCafe © 2024 · Privacy · Terms